Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kerry Berghoff

Nurse Practitioner Chandler, AZ Nurse Practitioner

NPI 1093095671 CMS profile 11057992

705 S Dobson Rd, Chandler, AZ 85224

Open in the dashboard

General payments

$10,001

400 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kerry Berghoff of Chandler, AZ is reported in the CMS Open Payments database as having received $10,001 across 400 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,577 139
2024 General $2,284 76
2023 General $2,384 103
2022 General $1,312 60
2021 General $444 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kerry Berghoff
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kerry Berghoff were reported at $3,577. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kerry Berghoff Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $444 $135 $40–$426 $132
2022 $1,312 $152 $48–$470 $149
2023 $2,384 $166 $54–$529 $160
2024 $2,284 $173 $55–$556 $164
2025 $3,577 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $1,242 52 payments
  2. AstraZeneca Pharmaceuticals LP $1,152 25 payments
  3. CSL Behring $769 24 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $710 40 payments
  5. Genentech USA, Inc. $576 18 payments
  6. Grifols USA, LLC $541 28 payments
  7. ADMA BioManufacturing LLC $499 28 payments
  8. Genzyme Corporation $489 16 payments
  9. Amgen Inc. $460 15 payments
  10. Pharming Healthcare, Inc. $398 13 payments
  11. Other $3,165 141 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,415 368 payments
  2. Consulting Fee $315 24 payments
  3. Education $271 8 payments
Products named General payments · program years 2021–2025
  1. TEZSPIRE Respiratory $810 9 payments
  2. DUPIXENT Inflammation And Immunology $800 36 payments
  3. DUPIXENT Immunology $688 23 payments
  4. Xolair $670 19 payments
  5. AIRSUPRA $637 10 payments
  6. FASENRA $631 9 payments
  7. Xembify $541 28 payments
  8. TEZSPIRE Inflammation $446 14 payments
  9. DUPIXENT Immunology And Inflammation $443 16 payments
  10. CUVITRU $414 23 payments
  11. Other $5,259 223 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

530

Median for Nurse Practitioner: 389

Drug cost

$203,294

Median for Nurse Practitioner: $21,885

Branded share of claims

40.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 22 $59,640
Dupixent Syringe Dupilumab Brand 14 $52,254
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 45 $34,574
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 18 $12,491
Breo Ellipta Fluticasone/Vilanterol Brand 22 $10,039
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 16 $8,317
Cromolyn Sodium Generic 13 $6,004
Symbicort Budesonide/Formoterol Fumarate Brand 11 $5,811
Epinephrine Generic 22 $4,816
Azelastine Hcl Generic 90 $3,503

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XOLAIR
  • Genentech USA, Inc. $273
  • Novartis Pharmaceuticals Corporation $84
$357 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $185
  • SANOFI-AVENTIS U.S. LLC $100
$285 14 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $206
$206 — —
TEZSPIRE
  • Amgen Inc. $116
  • AstraZeneca Pharmaceuticals LP $83
$199 — —
Hizentra
  • CSL Behring $142
$142 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

400 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record